IGMS News and Press, IGM Biosciences Inc. From 03/31/23

2023-03-31 23:06:06 ET IGM Biosciences, Inc. (IGMS) Q4 2022 Earnings Conference Call March 30, 2023 4:30 PM ET Company Participants Fred Schwarzer – Chief Executive Officer Misbah Tahir – Chief Financial Officer Chris Takimoto – Chief Medical...

– Encouraging initial data from IGM-8444 combination with FOLFIRI; first patient dosed in randomized trial – – Imvotamab to move forward into clinical studies in multiple autoimmune diseases – – Initiation of Phase 1 clinical trial for targeted...

MOUNTAIN VIEW, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that it will report its fourth quarter and full year 2022 financial results on Thurs...

2023-03-17 14:24:28 ET Wall Street’s attention has turned away from corporate earnings and has been understandably drawn to uncertainty in the financial industry and the Federal Reserve’s upcoming decision. Still, earnings chug along into the penultimate week of March, wit...

2023-03-13 08:00:00 ET Summary IGM Biosciences, Inc. is a leader in IgM antibody development. It stuck a major deal with Sanofi last year. Decent data, proof of concept, and good cash runway make IGM Biosciences, Inc. attractive. Just a year ago, I covered IGM Bi...

MOUNTAIN VIEW, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at ...

IGM Biosciences ( NASDAQ: IGMS ) said the first patient was dosed in a phase 1 trial of IGM-7354 for solid tumors. IGM-7354 is a targeted IL-15/IL-15R IgM antibody which could potentially be used to treat patients with solid tumors and blood cancers. The study will evalua...

MOUNTAIN VIEW, Calif., Jan. 17, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that the first patient has been dosed in its Phase 1 clinical trial evaluating IGM-73...

– Initial Data from Phase 1 combination with FOLFIRI shows promising activity in heavily pretreated metastatic colorectal cancer patients – – Encouraging safety profile in combination with FOLFIRI chemotherapy – – Randomized combination trial...

Summary Baker Brothers’ 13F portfolio value decreased from $17.63B to $15.27B this quarter. Rhythm Pharma and Akero Therapeutics were increased while decreasing argenx SE and Horizon Therapeutics. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they a...